The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation
Open accessAbstract
The intracellular levels of many proteins are regulated by ubiquitin-dependent proteolysis. One of the best-characterized enzymes that catalyzes the attachment of ubiquitin to proteins is a ubiquitin ligase complex, Skp1-Cullin-F box complex containing Hrt1 (SCF). We sought to artificially target a protein to the SCF complex for ubiquitination and degradation. To this end, we tested methionine aminopeptidase-2 (MetAP-2), which covalently binds the angiogenesis inhibitor ovalicin. A chimeric compound, protein-targeting chimeric molecule 1 (Protac-1), was synthesized to recruit MetAP-2 to SCF. One domain of Protac-1 contains the IκBα phosphopeptide that is recognized by the F-box protein β-TRCP, whereas the other domain is composed of ovalicin. We show that MetAP-2 can be tethered to SCF β -TRCP , ubiquitinated, and degraded in a Protac-1-dependent manner. In the future, this approach may be useful for conditional inactivation of proteins, and for targeting disease-causing proteins for destruction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Proteolysis-targeting chimeras (PROTACs) are bifunctional molecules designed to simultaneously engage a protein of interest and the cell’s ubiquitination machinery, facilitating the ubiquitination of the target protein [73,74].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [74]
In the citing paper
“Bivalent degraders, such as proteolysis-targeting chimeras (PROtAcs) operate through the principle of induced proximity (Sakamoto et al. 2001;Deshaies 2015).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Sakamoto et al. 2001
In the citing paper
“the concept of targeted protein degradation was first introduced by crews, Deshaies and colleagues in 2001 (Sakamoto et al. 2001).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Sakamoto et al. 2001
In the citing paper
“Within this complex, the target protein is tagged with ubiquitin, facilitating its recognition and subsequent degradation by the proteasome.480,481”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [481]
In the citing paper
“As a heterobifunctional molecule, PROTAC simultaneously targets the protein of interest and the E3 ubiquitin ligase, forming a ternary complex.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [481]
In the citing paper
“At the core of PROTAC’s mechanism of action lies the degradation of target proteins via the ubiquitin-proteasome system (UPS).”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [481]
In the citing paper
“TPD uses small molecules (degraders) to hijack the cellular degradation machinery by recruiting E3 ubiquitin ligases to proteins of interest (POI), which would not otherwise be recognized as substrates (Sakamoto et al., 2001)”
From Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development (2020) · cites this paper as Sakamoto et al., 2001
In the citing paper
“If these two groups are connected via a carefully-chosen chemical linker, the resulting compound can induce formation of a ternary complex that includes the target protein, the PROTAC, and the E3 ligase. The resulting proximity between target protein and E3 ligase can then lead to ubiquitination of the target protein, and ultimately its degradation 1.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [1]
In the citing paper
“Protac-1 acted as a tether between METAP2 and β-TRCP, enabling the ligase to ubiquitylate METAP2 in extracts from unfertilized Xenopus laevis eggs.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [9]
In the citing paper
“In vitro proof of concept for the first fully synthetic PROTAC, dubbed Protac-1, was reported in 2001 (ref.9).”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [9]
In the citing paper
“a concept originally proposed in the landmark PROTAC paper by Sakamoto et al.9 20 years ago.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [9]
In the citing paper
“The first PROTAC described consisted of an ovalicin headgroup that bound methionine-aminopeptidase 2 (MetAP-2) linked to an IκBα derived peptide headgroup that bound the Skp1–cullin–F-Box (SCF) complex [62].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [62]
In the citing paper
“This molecule efficiently degraded MetAP-2 in Xenopus oocyte extracts, however it was not cell permeable [62].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [62]
In the citing paper
“BTRC was efficiently recruited by PROTACs composed of a BTRC-interacting peptide and small-molecule ligands for METAP2, the oestrogen or androgen receptors, leading to degradation of their respective targets 2,113 .”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [2]
Citations
Cites
Phosphorylation meets ubiquitination: the control of NF-κB activity
Karin, M., & Ben-Neriah, Y. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.621 · Cited by 4,766
IKK-1 and IKK-2: Cytokine-Activated IκB Kinases Essential for NF-κB Activation
Mercurio, F., Zhu, H., Murray, B. W., Shevchenko, A., Bennett, B. L., Li, J. W., Young, D. B., Barbosa, M. S., Mann, M., Manning, A. M., et al. (1997) · Science · doi:10.1126/science.278.5339.860 · Cited by 2,042
Self-citationSCF and Cullin/RING H2-Based Ubiquitin Ligases
Deshaies, R. J. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.435 · Cited by 1,238
Self-citationChapter 30 Cell Cycle Extracts
Murray, A. W. (1991) · Methods in cell biology · doi:10.1016/s0091-679x(08)60298-8 · Cited by 942
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity
Meng, L., Mohan, R., Kwok, B. H. B., Elofsson, M., Sin, N., & Crews, C. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10403 · Cited by 938
Self-citationNagahara, H., Vocero-Akbani, A. M., Snyder, E. L., Ho, A. L., Latham, D. G., Lissy, N. A., Becker‐Hapak, M., Ezhevsky, S. A., & Dowdy, S. F. (1998) · Nature Medicine · doi:10.1038/4042 · Cited by 928
Ubiquitin-mediated proteolysis: biological regulation via destruction
Ciechanover, A. J., Orian, A., & Schwartz, A. L. (2000) · BioEssays · doi:10.1002/(sici)1521-1878(200005)22:5 · Cited by 848
Margottin-Goguet, F., Bour, S. P., Durand, H., Selig, L., Bénichou, S., Richard, V., Thomas, D., Strebel, K., & Bénarous, R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80056-8 · Cited by 670
Identification of the receptor component of the IκBα–ubiquitin ligase
Yaron, A., Hatzubai, A., Davis, M., Lavon, I., Amit, S., Manning, A. M., Andersen, J., Mann, M., Mercurio, F., & Ben‐Neriah, Y. (1998) · Nature · doi:10.1038/25159 · Cited by 654
Self-citationSin, N., Meng, L., Wang, M. Q. W., Wen, J., Bornmann, W. G., & Crews, C. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6099 · Cited by 634
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–165 of 165
DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
Li, F., Hu, Q., Zhang, X., Sun, R., Liu, Z., Wu, S., Tian, S., Ma, X., Dai, Z., Yang, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34807-3 · Cited by 159
Sun, Y., Ding, N., Song, Y., Yang, Z., Liu, W., Zhu, J., & Rao, Y. (2019) · Leukemia · doi:10.1038/s41375-019-0440-x · Cited by 148
Mutant-selective degradation by BRAF-targeting PROTACs
Alabi, S., Jaime-Figueroa, S., Yao, Z., Gao, Y., Hines, J., Samarasinghe, K. T. G., Vogt, L., Rosen, N., & Crews, C. M. (2021) · Nature Communications · doi:10.1038/s41467-021-21159-7 · Cited by 152
Self-citationPopow, J., Arnhof, H., Bader, G., Berger, H., Ciulli, A., Covini, D., Dank, C., Gmaschitz, T., Greb, P., Karolyi-Özguer, J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01826 · Cited by 138
Selective degradation of CDK6 by a palbociclib based PROTAC
Rana, S., Bendjennat, M., Kour, S., King, H. M., Kizhake, S., Zahid, M., & Natarajan, A. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.03.035 · Cited by 135
Targeting IRAK4 for Degradation with PROTACs
Nunes, J., McGonagle, G. A., Eden, J., Kiritharan, G., Touzet, M., Lewell, X., Emery, J., Eidam, H., Harling, J. D., & Anderson, N. A. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00219 · Cited by 134
Zhao, Q., Ren, C., Liu, L., Chen, J., Shao, Y., Sun, N., Sun, R., Kong, Y., Ding, X., Zhang, X., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01264 · Cited by 134
Defining molecular glues with a dual-nanobody cannabidiol sensor
Cao, S., Kang, S., Mao, H., Yao, J., Gu, L., & Zheng, N. (2022) · Nature Communications · doi:10.1038/s41467-022-28507-1 · Cited by 125
A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
Bery, N., Miller, A., & Rabbitts, T. (2020) · Nature Communications · doi:10.1038/s41467-020-17022-w · Cited by 132
Ligandability of E3 Ligases for Targeted Protein Degradation Applications
Belcher, B. P., Ward, C. C., & Nomura, D. K. (2023) · Biochemistry · doi:10.1021/acs.biochem.1c00464 · Cited by 132
Integrative Modeling of PROTAC-Mediated Ternary Complexes
Weng, G., Li, D., Kang, Y., & Hou, T. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01576 · Cited by 130
Targeted protein degradation and the enzymology of degraders
Fisher, S. L., & Phillips, A. J. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.004 · Cited by 126
Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery
Pei, J., Wang, G., Feng, L., Zhang, J., Jiang, T., Sun, Q., & Ouyang, L. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01689 · Cited by 124
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126
Mayor-Ruiz, C., Jaeger, M. G., Bauer, S., Brand, M., Sin, C., Hanzl, A., Mueller, A. C., Menche, J., & Winter, G. E. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.013 · Cited by 119
Okuhira, K., Ohoka, N., Sai, K., Nishimaki-Mogami, T., Itoh, Y., Ishikawa, M., Hashimoto, Y., & Naito, M. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.019 · Cited by 118
Hamilton, E. P., Ma, C., De Laurentiis, M., Iwata, H., Hurvitz, S. A., Wander, S. A., Danso, M., Lu, D. R., Perkins Smith, J., Liu, Y., et al. (2024) · Future Oncology · doi:10.1080/14796694.2024.2377530 · Cited by 116
Conditional control of fluorescent protein degradation by an auxin-dependent nanobody
Daniel, K., Icha, J., Horenburg, C., Müller, D., Norden, C., & Mansfeld, J. (2018) · Nature Communications · doi:10.1038/s41467-018-05855-5 · Cited by 113
Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes
Schiemer, J., Horst, R., Meng, Y., Montgomery, J. I., Xu, Y., Feng, X., Borzilleri, K., Uccello, D. P., Leverett, C., Brown, S., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-020-00686-2 · Cited by 113
Cereblon modulators: Low molecular weight inducers of protein degradation
Chamberlain, P. P., & Cathers, B. E. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.02.004 · Cited by 106
From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1)
Papatzimas, J. W., Gorobets, E., Maity, R., Muniyat, M. I., MacCallum, J. L., Neri, P., Bahlis, N. J., & Derksen, D. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00455 · Cited by 103
Link-INVENT: Generative Linker Design with Reinforcement Learning
Guo, J., Knuth, F., Margreitter, C., Janet, J. P., Papadopoulos, K., Engkvist, O., & Patronov, A. (2022) · doi:10.26434/chemrxiv-2022-qkx9f · Cited by 101
PROTAC degraders as chemical probes for studying target biology and target validation
Němec, V., Schwalm, M. P., Müller, S., & Knapp, S. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00478j · Cited by 98
Advances in targeted degradation of endogenous proteins
Röth, S., Fulcher, L. J., & Sapkota, G. P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03112-6 · Cited by 92
An affinity-directed protein missile system for targeted proteolysis
Fulcher, L. J., Macartney, T., Bozatzi, P., Hornberger, A., Rojas-Fernandez, A., & Sapkota, G. P. (2016) · Open Biology · doi:10.1098/rsob.160255 · Cited by 91
PROTAC therapy as a new targeted therapy for lung cancer
Li, J. W., Zheng, G., Kaye, F. J., & Wu, L. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.011 · Cited by 87
Jaime-Figueroa, S., Buhimschi, A. D., Toure, M., Hines, J., & Crews, C. M. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126877 · Cited by 88
Self-citationZhang, X., Thummuri, D., He, Y., Liu, X., Zhang, P., Zhou, D., & Zheng, G. (2019) · Chemical Communications · doi:10.1039/c9cc07217a · Cited by 86
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00844 · Cited by 100
Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders
Yang, X., Wang, Z., Pei, Y., Song, N., Xu, L., Feng, B., Wang, H., Luo, X., Hu, X., Qiu, X., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113341 · Cited by 85
UBE2G1 governs the destruction of cereblon neomorphic substrates
Lu, G., Weng, S., Matyskiela, M., Zheng, X., Fang, W., Wood, S., Surka, C., Mizukoshi, R., Lu, C.-C., Mendy, D., et al. (2018) · eLife · doi:10.7554/elife.40958 · Cited by 78
Targeting endogenous proteins for degradation through the affinity-directed protein missile system
Fulcher, L. J., Hutchinson, L. D., Macartney, T. J., Turnbull, C., & Sapkota, G. P. (2017) · Open Biology · doi:10.1098/rsob.170066 · Cited by 79
Development of selective small molecule MDM2 degraders based on nutlin
Wang, B., Wu, S., Liu, J., Yang, K., Xie, H., & Tang, W. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.046 · Cited by 77
Bai, N., Riching, K. M., Makaju, A., Wu, H., Acker, T. M., Ou, S.-C., Zhang, Y., Shen, X., Bulloch, D. N., Rui, H., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101653 · Cited by 77
PIKES Analysis Reveals Response to Degraders and Key Regulatory Mechanisms of the CRL4 Network
Reichermeier, K. M., Straube, R., Reitsma, J. M., Sweredoski, M. J., Rose, C. M., Moradian, A., den Besten, W., Hinkle, T., Verschueren, E., Petzold, G., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2019.12.013 · Cited by 78
Self-citationAllostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs
Nussinov, R., Zhang, M., Maloney, R., Liu, Y., Tsai, C.-J., & Jang, H. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167569 · Cited by 66
Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs
Anderson, N. A., Cryan, J., Ahmed, A., Dai, H., McGonagle, G. A., Rozier, C., & Benowitz, A. B. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127106 · Cited by 69
Hatakeyama, S., Watanabe, M., Fujii, Y., & Nakayama, K. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1581 · Cited by 67
Feng, L., Wang, G., Chen, Y., He, G., Liu, B., Liu, J., Chiang, C., & Ouyang, L. (2022) · Medicinal Research Reviews · doi:10.1002/med.21859 · Cited by 65
Acetylation targeting chimera enables acetylation of the tumor suppressor p53
Kabir, M., Sun, N., Hu, X., Martin, T. C., Yi, J., Zhong, Y., Xiong, Y., Kaniskan, H. Ü., Gu, W., Parsons, R., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c04640 · Cited by 65
Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries
Wang, B., Liu, J., Tandon, I., Wu, S., Teng, P., Liao, J., & Tang, W. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113425 · Cited by 67
A novel cereblon modulator for targeted protein degradation
Kim, S. A., Go, A., Jo, S.-H., Park, S. J., Jeon, Y. U., Kim, J. E., Lee, H. K., Park, C. H., Lee, C.-O., Park, S. G., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.023 · Cited by 72
Mallucci, G. R., Klenerman, D., & Rubinsztein, D. C. (2020) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-040320-120625 · Cited by 62
Development of covalent inhibitors: Principle, design, and application in cancer
Zheng, L., Li, Y., Wu, D., Xiao, H., Zheng, S., Wang, G., & Sun, Q. (2023) · MedComm – Oncology · doi:10.1002/mog2.56 · Cited by 71
Hydrophobic tagging-mediated degradation of Alzheimer's disease related Tau
Gao, N., Chu, T.-T., Li, Q.-Q., Lim, Y.-J., Qiu, T., Ma, M.-R., Hu, Z.-W., Yang, X.-F., Chen, Y.-X., Zhao, Y.-F., et al. (2017) · RSC Advances · doi:10.1039/c7ra05347a · Cited by 62
Qu, L., Li, S., Ji, L., Luo, S., Ding, M., Yin, F., Wang, C., Luo, H., Lu, D., Liu, X., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113889 · Cited by 61
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Ash, L. J., Busia-Bourdain, O., Okpattah, D., Kamel, A., Liberchuk, A., & Wolfe, A. L. (2024) · Current Oncology · doi:10.3390/curroncol31040150 · Cited by 68
“These vaccines are designed to induce antigen-presenting cells to display mutant KRAS, stimulating attacks by cytotoxic T-cells against cancer cells expressing mutant KRAS neoantigen [78–80].”
BackgroundMa, Y., Gu, Y., Zhang, Q., Han, Y., Yu, S., Lu, Z., & Chen, J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0650 · Cited by 55
A critical evaluation of the approaches to targeted protein degradation for drug discovery
Chopra, R., Sadok, A., & Collins, I. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.02.002 · Cited by 53
Jiang, F., Wei, Q., Li, H., Li, H., Cui, Y., Ma, Y., Chen, H., Cao, P., Lu, T., & Chen, Y. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115181 · Cited by 48
Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
Li, X., Liu, Q., Xie, X., Peng, C., Pang, Q., Liu, B., & Han, B. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01712 · Cited by 46
IFITM proteins assist cellular uptake of diverse linked chemotypes
Lou, K., Wassarman, D. R., Yang, T., Paung, Y., Zhang, Z., O’Loughlin, T. A., Moore, M. K., Egan, R. K., Greninger, P., Benes, C. H., et al. (2022) · Science · doi:10.1126/science.abl5829 · Cited by 42
Small-Molecule Degraders beyond PROTACs—Challenges and Opportunities
Kastl, J. M., Davies, G., Godsman, E., & Holdgate, G. A. (2021) · SLAS Discovery · doi:10.1177/2472555221991104 · Cited by 43
Niedermolekulare PROTACs: neue Wege zum Abbau von Proteinen
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie · doi:10.1002/ange.201507978 · Cited by 40
Self-citationXie, B., Yin, Z., Hu, Z., Lv, J., Du, C., Deng, X., Huang, Y., Li, Q., Huang, J., Liang, K., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02032 · Cited by 39
Molecular glue degraders: exciting opportunities for novel drug discovery
Lemaitre, T., Cornu, M., Schwalen, F., Since, M., Kieffer, C., & Voisin-Chiret, A. S. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2306845 · Cited by 36
Identification and characterization of cancer vulnerabilities via targeted protein degradation
Mayor-Ruiz, C., & Winter, G. E. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2018.12.003 · Cited by 33
Scrutinizing the Therapeutic Potential of PROTACs in the Management of Alzheimer’s Disease
Bhatia, S., Singh, M., Singh, T., & Singh, V. (2023) · Neurochemical Research · doi:10.1007/s11064-022-03722-w · Cited by 22
Targeted protein modification as a paradigm shift in drug discovery
Amirian, R., Azadi Badrbani, M., Izadi, Z., Samadian, H., Bahrami, G., Sarvari, S., Abdolmaleki, S., Nabavi, S. M., Derakhshankhah, H., & Jaymand, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115765 · Cited by 18
Faber, S., Lahoti, T., Taylor, E., Lewis, L., Sapiro, J., Toledo Sales, V., Dragan, Y., & Jeffy, B. (2022) · Cells · doi:10.3390/cells11101708 · Cited by 16
From serendipity to strategy: molecular glue degraders in cancer therapeutics
Darling, S., Bajrami, I., & West, S. C. (2025) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2025.2564068 · Cited by 9
“…while auxin was the first molecular glue degrader to be described, it was not the first recorded use of induced proximity as a tool for targeted protein degradation. the concept of targeted protein degradation was first introduced by crews, Deshaies and colleagues in 2001 (Sakamoto et al. 2001).”
Wang, Y., Deng, S., & Xu, J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0066 · Cited by 10
Dixon, T., MacPherson, D., Mostofian, B., Dauzhenka, T., Lotz, S., McGee, D., Shechter, S., Shrestha, U. R., Wiewiora, R., McDargh, Z. A., et al. (2021) · doi:10.1101/2021.09.26.461830 · Cited by 7
Design and synthesis of novel bispecific molecules for inducing BRD4 protein degradation
Wang, S., Song, Y., Wang, Y., Gao, Y., Yu, S., Zhao, Q., Jin, X., & Lu, H. (2018) · Chemical Research in Chinese Universities · doi:10.1007/s40242-018-7272-5 · Cited by 6
Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues
Ojeda, S., Wang, M., Baek, K., Bourgeois, W., Sommerschield, A., Yue, H., Metivier, R. J., Karagiannis, P., Levitz, T. S., Xiong, Y., et al. (2026) · Science · doi:10.1126/science.aef5391 · Cited by 5
Metadata
- Authors
- Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J.
- Affiliations
- California Institute of Technology (US)
- Corresponding author
- Deshaies, Raymond J.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2001-07-03
- Volume
- 98
- Issue
- 15
- Pages
- 8554-8559
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC37474
- OpenAlex
- W2151683271
- Cited by
- 2,609
- References
- 25
- Citations by year
- 2026: 355 · 2025: 435 · 2024: 399 · 2023: 309 · 2022: 278 · 2021: 224 · 2020: 193 · 2019: 118 · 2018: 75 · 2017: 48 · 2016: 28 · 2015: 15 · 2014: 13 · 2013: 9 · 2012: 10
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Leukemia and Lymphoma Society
- University of California, Los Angeles
- Jonsson Comprehensive Cancer Center
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- PROTACs, chimeric molecules, SCF ubiquitin ligase, β-TrCP, ubiquitination, protein degradation, targeted protein degradation
- MeSH terms
- NF-KappaB Inhibitor alpha, Aminopeptidases, Animals, Cell Extracts, Cell Line, Transformed, DNA-Binding Proteins, Humans, Metalloendopeptidases, Ovum, Peptide Synthases, Protein Binding, Recombinant Fusion Proteins, Ubiquitins, Xenopus laevis, I-kappa B Proteins, SKP Cullin F-Box Protein Ligases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
